HIPRA
↗Amer, Spain
HIPRA is a Spanish multinational biotechnological pharmaceutical company focused on the research, production, and commercialization of biological products for animal and human health. Founded in 1971, the company is a world leader in animal health, particularly known for its extensive portfolio of vaccines and diagnostic services for both production and companion animals.
In recent years, HIPRA has expanded into human health, notably developing a recombinant protein vaccine against COVID-19 (Bimervax). The company operates with a high degree of vertical integration, controlling its entire value chain, and maintains a strong global presence with subsidiaries in 40 countries, multiple R&D centers, and production facilities across Europe and South America.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Pharmaceuticals
Sub-Industry:Veterinary Vaccines and Diagnostics
SIZE & FINANCIALS
Employees:1001-5000
Founded:1971
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Recombinant protein vaccines, Biologics
Trial Phases:-
FDA Approvals:0
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:GoodGut
Key Partnerships:Accord Healthcare (Commercialization of COVID-19 vaccine in UK), Veeva Systems (Digital commercial strategy)
COMPETITION
Position:Leader
Competitors:Zoetis, Boehringer Ingelheim Animal Health, MSD Animal Health, Elanco, Virbac
LEADERSHIP
Key Executives:
David Nogareda - CEO
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of HIPRA and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with HIPRA. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.